Gen-Probe, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$2.7Mgeneral payments (2019-2025)
$37Kresearch payments (2019-2025)
298clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Aptima $1.6M associated (2023-2025)
- None $63K associated (2023-2025)
- Fetal Fibronectin Enzyme Immunoassay $56K associated (2023-2025)
- Thinprep 2000 Processor $54K associated (2023-2025)
- Localizer $6,124 associated (2023-2025)
- Panther Fusion $5,767 associated (2023-2025)
- Genius Ai Detection $5,515 associated (2023-2025)
- I -View Contrast Enhanced Digital Mammography $3,151 associated (2023-2025)
- Btx $1,796 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Darren Wheeler | Las Vegas, NV | Anatomic Pathology | $434,226.48 |
| Michael Ruma | Albuquerque, NM | Maternal & Fetal Medicine | $404,891.23 |
| Melissa Martinez Adorno | Nashua, NH | Obstetrics & Gynecology | $215,108.62 |
| Kyle Bukowski | Orlando, FL | Obstetrics & Gynecology | $209,914.61 |
| Neha Deshpande | Plainsboro, NJ | Obstetrics & Gynecology | $179,798.21 |
| Michael Randell | Atlanta, GA | Gynecology | $109,503.99 |
| Tonya Chaffee | San Francisco, CA | Pediatrics | $102,512.16 |
| Shruti Bala | Tucson, AZ | Obstetrics & Gynecology | $94,089.95 |
| Nealya Bell-Silva | Saint Louis, MO | Women'S Health (Nurse Practitioner) | $87,975.73 |
| Ada Stewart | Columbia, SC | Family Medicine | $72,980.47 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.